Pulmonx (LUNG) Consolidated Net Income (2019 - 2025)

Pulmonx (LUNG) has reported Consolidated Net Income for 7 consecutive years, with -$14.0 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Consolidated Net Income rose 1.38% year-over-year to -$14.0 million; the TTM figure through Dec 2025 stood at -$43.6 million (up 22.69% YoY), while the FY2024 annual figure was -$56.4 million, up 7.31% from the prior year.
• Consolidated Net Income improved to -$14.0 million in Q3 2025 per LUNG's latest filing, from -$15.2 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at -$10.2 million in Q3 2021 and bottomed at -$16.2 million in Q2 2023.
• Historically, Consolidated Net Income has averaged -$14.1 million across 5 years, with a median of -$14.2 million in 2022.
• Annual changes were most pronounced in 2021 — Consolidated Net Income slumped 163.76% — and 2024, when it advanced 13.22%.
• Pulmonx's Consolidated Net Income stood at -$13.0 million in 2021, then dropped by 9.89% to -$14.3 million in 2022, then gained by 2.77% to -$13.9 million in 2023, then advanced by 5.41% to -$13.1 million in 2024, then retreated by 6.24% to -$14.0 million in 2025.
• Business Quant data shows LUNG's Consolidated Net Income at -$14.0 million in Q3 2025, -$15.2 million in Q2 2025, and -$14.4 million in Q1 2025.